This could be why your weight-loss medication isn’t delivering results
Fox News • • health
Key Points:
- A study published in Nature found that a genetic variation in the GLP-1 receptor gene (GLP1R) can modestly boost the effectiveness of weight-loss drugs like semaglutide and tirzepatide, with carriers losing an average of 1.6 pounds more than non-carriers.
- The research, based on self-reported data from over 27,000 users, also identified a separate genetic variant linked to increased nausea and vomiting, side effects that did not reduce the drugs' weight-loss effectiveness.
- Women experienced greater BMI reduction than men, and factors such as age, sex, and specific medications were stronger predictors of weight-loss success than genetics alone.
- Experts caution that the study's reliance on self-reported data and lack of clinical verification may limit its reliability, and the observational design cannot establish causation between genetic variants and drug response.
- The findings suggest potential for personalized weight management through genetic testing, but further clinical research is needed to confirm these associations and guide treatment decisions.
